Tassi, R. A., Gambino, A., Ardighieri, L., Bignotti, E., Todeschini, P., Romani, C., . . . Ravaggi, A. (2019). FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients. Br J Cancer.
Citação norma ChicagoTassi, Renata A., et al. "FXYD5 (Dysadherin) Upregulation Predicts Shorter Survival and Reveals Platinum Resistance in High-grade Serous Ovarian Cancer Patients." Br J Cancer 2019.
MLA CitationTassi, Renata A., et al. "FXYD5 (Dysadherin) Upregulation Predicts Shorter Survival and Reveals Platinum Resistance in High-grade Serous Ovarian Cancer Patients." Br J Cancer 2019.
Advarsel: Disse citationer er muligvist ikke 100% nøjagtige.